Turning Point Therapeutics (TPTX) 12 May 202020 Q1 Earnings call transcript

Ladies and gentlemen, thank you for standing by, and welcome to the Turning Point Therapeutics' First Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the conference to your speaker today, Jim Mazzola. sir. ahead, go Please

everyone. afternoon, Good

market close issued our Form and filed for today, news release we XXXX. a of of first our with the XX-Question, quarter Following a results summary

updated also our presentation. We investor

these find of may the Investor documents You pages tptherapeutics.com. on posted

today our call Point's Turning a our COVID-XX CFO, to business Dr. results, be Executive an overview pandemic. President will the will by Countouriotis, including review who will financials provide Chief be Athena's and Officer, by the Larson. Leading Yi and Athena our update followed remarks on of response our

remarks. We will take questions following our prepared

As guidelines locations remote of and a are company, the are us we adhering today. for social three therefore and to distancing different in work,

Q&A session. previously recorded prepared have which our live we after We a remarks, will host

this bear results us approach issues. please in technical with if modified any So

indicated you materially I Athena call results will be begins, Before Company's those forward-looking to from may expressed such we want actual during conference The or forward-looking statements. statements. by making differ this that remind in

a Securities For to with factors filings in investing recent our please with the Point associated Therapeutics, Exchange Turning refer Commission. of and description risk

let the me to over Now, call Athena. turn

afternoon Jim, us joining Thank and to today. you, good everyone

COVID-XX. incredibly of team the now meaningful navigating update pleased rapidly in health quarter, want while many was sacrifices provide begin and these our remained to pandemic. focused the past am our so made to the therapies to wellbeing and incredibly I months past of on proud patients how and the the with quarter to situation of the one and the have every challenges, quarter, I our Before our patients and especially progress on this who during providers to bring for response made we have challenging goals an in many worldwide. the each so evolving need, acknowledge society, thank dedicated Despite for healthcare I few

developed cancer. we if key utilized and the lung address Turning pipeline targeted non-small-cell next-generation Point are of with and in our development Phase target of with story, active majority our tyrosine with first X each up of discovered the four candidates we the that activations, as anyone the kinase of have XX% of single of Today, Europe cancer internally drug Asia-Pacific and global to at with quarter, and have across sites our advanced opportunity to specifically to therapy drivers site includes rate inhibitors starting the our of wholly In new in potential For repotrectinib, programs owned genetic remained agents, XX the study. pleased our sites approximately This TRIDENT-X region. countries. now we activated sites XX% the U.S. numerous

TRIDENT-X portion sites to is The of at approximately patients, globally. expected XXX now XXX up to Phase X enroll

patients continue early walk of to I we second-half addition, additional initial In I from our interim as will some anticipate the year. of data cohorts in detail the registration that providing milestones. update the for upcoming through provide during

oversight for committee the Their our of the repotrectinib The responsible the initial to profile based of the portion TRIDENT-X study. evaluation is completed also recommendation We the on was safety independent trial study. recently DMT the safety monitoring continue. for X meeting first and of overall for conduct data Phase the within study

videoconference. remotely evaluate sites, CROs, pandemic, of progress very a with trial, updates not to the IRBs. the were phone our on our we which and allowing by included patients collaboration data enabling our monitoring, or These is and during made remote steps impact and activation to multiple certain challenging to enrollment routine took periodic give to mitigate registration have tests standard the with closer I implemented home, remain to site practice help their quarter. measures We first pleased it conducted While patients in our in sites ongoing

additional we X evaluated have in sites our study. TRIDENT-X addition, Phase also participation for In

experienced we interruptions we to site clinical the the started any supply initiation study. experience more delays Importantly, and recently have not enrollment mitigate in COVID-XX of to the related have within impact our COVID-XX, steps programs. to trials Despite patient TRIDENT-X

We are studies, and pandemic. continued the our depend watching also extent the progress and other of of will on on our the the in the impact closely duration believe pipeline severity

in ongoing pediatric to X/X Turning studies, stage to assess an three solid study ALK positive we have TRK tumors. label or advanced and Phase ROSX patients our first, earlier with open repotrectinib

to We study with continue advance that and enrollment. patient activations site

MET genetic TPX-XXXX, alterations in SRC X solid Phase MET. in with our Next open study our inhibitor advanced label patients and is CSFXR harboring of tumors

help the As tolerated and designed or we escalation expectations, primarily be dose, will through early is update guide preliminary overall from has a of the anticipate to well pretreated a this with continue enrolled a anticipate TKI-naïve maximum dose early MET TPX-XXXX. patients cohorts. reporting amplifications, and interim profile, in escalation signals The determine reminder, primarily of as as initial any we dose To our both safety second-half efficacy study the study XXXX. we exon efficacy update alterations safety standard XX patients as and data

RET/SRC in is pipeline our our Next TPX-XXXX, inhibitor.

GXXXR preclinical potency including encouraged solvent-front type wild F. and TPX-XXXX are the on by potential against We based for and KIFXB-RET mutations, its

of the XX in the journal with published treated in a patients. For solvent-front positive five cell inhibitor of of of approximately total rate was Oncology RET mutations RET patients capmatinib XX% reference, XX or recent the Thoracic data indicated

with non-small-cell our TKI-naïve pretreated X/X enroll RET escalation While investigational mutations is to with progressing other prevalence TPX-XXXX both The ongoing is brought study altered preliminary, with portion cancers. and patients consistent other drivers, designed fibroid, TRK of and mutations other inhibitors. are oncogenic in the solid with with patients, and previously observed patients RET The including and including ROSX, study enrollment these advanced of data Phase of solvent-front treated lung, ALK. dose

solvent-front by goal has been nomination its studies enter early particular, announced the and compound January macrocyclic pipeline in with clinically is in the IND-enabling IND compact ALK has TPX-XXXX next-generation candidate. ALK inhibit to our mutation. been a mutations, with numerous shown preclinical inhibitor Lastly observed XXXX. potently studies an to and designed submitting TPX-XXXX, structure, our GXXXXR/LXXXXM mutation We in of ALK wild GXXXXR type and in

are and excited track this have remained advance We as during as candidate quickly preclinical on pandemic. to possible, activities with drug the

From our programs, during now and I we will update progress XXXX, provide our have each. milestones of anticipated an towards

the to second-half TRIDENT-X First, interim we during of as patients of guided from data the early a have of Phase cohorts some X in the reminder, study year. initial the registration providing

assessment in in provide data as sharing study approximately time, across are likely efficacy our a monitoring third We to overall study collection X position this in XX At dose be in anticipate this including Phase Phase the and X efficacy our evaluable quarter. size dataset it registrational relates and the update us that and global comparable patients multiple by our phase to safety XX conduct potentially preliminary a cohorts, evaluate will population. X at exploratory is we to X cohorts. ROSX Phase responses, to This currently potentially positive to overall our physician allow data to in

with this conferences would a goal monitoring closely medical given to update uncertainty subsequent of call. We this be news provide our are release and the and very

our any we data well we the for early the progress initial signals through escalation focus said on dose as safety, will update anticipate efficacy primarily update, TPX-XXXX I cohorts. earlier, as As as

milestone, have pleased at we abstracts ASCO virtual next annual our were to Moving to accepted upcoming several and the presentation AACR for meetings.

will ASCO. planned be for ASCO for by TPX-XXXX presentation poster for XX with Our update release a tomorrow abstracts preclinical scheduled on May

early presentations combination will repotrectinib late preclinical now present time will our data TPX-XXXX the should second TPX-XXXX. is ongoing to presentation. The virtual data this week, we goal abstracts at XXXX. of of meeting. work shared AACR, and an presentations be towards for AACR part plans for of in for can We For preclinical these date the submission and that June, poster the later IND preclinical our release our which AACR indicate data confirm by

update Now, call Yi the an results. to our let financial me on turn for over

Athena. Thank you,

that in part the included existing stock-based one-time million of financial transition first million, modifications company's will press expense non-cash of as agreement release a quarter our option compensation $XX.X scientific and associated and the expenses of vesting for the You see grants were the to founder. of tables stock with operating $XX.X

Excluding XXXX made and of of in compared the million, expenses GAAP of $XX.X including quarter in quarter operating repotrectinib pipeline, our the were the million million year-over-year investments rest non-GAAP to and have one-time totaled in QX first $XX.X $XX.X the we fourth the item, operating to added. develop Primary this increase expenses headcount drivers XXXX. of of

a in $XX.X operating of primarily million Reported one-time expenses, total of $XX.X included comprised compensation stock-based non-cash expenses items. the million

and use securities stage execute at make to during across We $XX.X XXXX earlier efforts. will were program fund cash continue a for first increase to trials marketable million quarter assets in expenses March and three XXXX. the our will clinical our and and our into We develop current XXst was position clinical $XXX.X project four as cash stage million. operations we cash Net equivalents expect investments discovery cash, health

back With Athena. that will update, I brief it to turn

patients summarize repotrectinib update meeting This for depend meeting COVID-XX the initial and trials. a potentially Phase include and on XX, We study providing is update XX TPX-XXXX of virtual AACR early this of interim June, submission, XXXX. the the advancing from To our each second-half enrollment late clear data at advancing preclinical our will with anticipate of second-half our and The in third treated Yi. quarter. data during the the for patients and multiple you, of Thank cohorts, TPX-XXXX preclinical our IND from clinical the year, area May in extent TRIDENT-X the ASCO of X enrollment year, the our an close, for efficacy towards during data update exploratory combination data data, impacts we I and across preclinical trial preliminary our TPX-XXXX presenting for anticipate in XX early safety pandemic. presenting a the clinical providing Phase will the goals initial on focus will duration in cohorts, approximately the including interim year, which in the on are registration patients from team, which virtual of TPX-XXXX to data collection at X

yet time great so for open now remained This our well patients. variables, accomplished want for this line to has many Operator, incredibly team I to all team rapidly Point and they delivering pipeline our Turning focused far adapted the you challenging our questions. thank Again, evolving been a with on may year.

Good afternoon, everyone.

was non-small-cell ROSX+ not Designation lung been today, the that Fast cancer previously what granted Drug for remarks. by to addition Track In been the inhibitor. in treatment kinase of Earlier U.S. treated repotrectinib have ROSX tyrosine our advanced with who Administration has outlined prepared we and patients Food announced a

for there Designation treatment of advanced non-small-cell had Track a reminder treated previously been prior of chemotherapy, based TKI, Fast the in repotrectinib one As patients January, a are Platinum ROSX who setting prior was where granted with and no lung line targeted currently approved therapies. cancer ROSX-positive of line a one

XX% utilizing was XX% or date cutoff latest of data median and XXXX months, XX months, estimation. response rate based Our of XX XX demonstrated the Designation XX or was blinded of ROSX-positive months Meier responders duration XX% Track repotrectinib The with a with also on of XX.X a confirmed up to lung granted of by TKI-naïve independent a to greater a nine of greater Fast central greater response overall equal than months, July equal XX non-small-cell or of a months, than than follow response of XX%, cancer patients in duration Kaplan is patients median this respectively. XX.X with review probability

which historical showed with months, study XX.X progression Repotrectinib survival not two this setting. a free X agents compares comparisons while endpoint of currently also Phase approved in favorably of for an the median

of patients April or partial of than a more for X XX follow-up, remained patients of seven remaining cutoff years, the or the months, the the with or July patients total six months data XXnd per X.X months analysis. more response repotrectinib. of TKI-naive to since the duration time on than XX.X responding remained ROSX XX% physician and an on additional plus more seven assessment two treatment than and from on of data with on at months for As of of treatment XX XX X.X XX% treatment for XXXX XX% five three XXXX All the in four treatment ranged

with patients the the April also the for of demonstrated XXX with months ROSX-positive given rate cutoff lung patients very has activity which repotrectinib this XXXX disease is months, with of with intracranial X patients who of therapeutic CNS data three as XX.X addition, among of non-small-cell of ROSX In durations options treatment and All patients on plus TKI-naïve July advanced cancer and plus, months. plus encouraging XX.X response XX CNS remain XX.X these response in analysis, objective of XX.X are XX.X as limited XX plus months, setting. XXX%, plus

information from TRIDENT-X may we study our up outlines, additional now that thank the our With X line Designation and for questions, recent Operator, Phase now Track Fast you. open

Sachs. you. comes Instructions] question [Operator Goldman Choi with Thank Our from first Paul

Your is line now open.

this product was an wondering out potential ongoing your study Paul. approved with Hi, for see point XXXX last [ph] on in of if the and of I anything on availability Corinne [Ph]? you the enrollment week, Jenkins wire] approved is [plasma] the any whether there's label impact to [for you'd the

approvals week two questions. was in hope targeted you busy for with the oncology family. obviously thank space. I the week, and everything's okay with Hi, a Last you Corinne, your

all approval orrepotrectinib of we capmatinib outlined. the I you've think anticipated

I a very think that drug. think good I've consistently it's I always said

that those precaution how think it that to have as relates drug of differentiates. may them, our been warnings to changes debate I'll always information, and/or I response leave detected focused on but duration we've and

I its as areas differentiate also precaution SRC is that selectivity be and hit one of we that the there do clearly so versus may and VEGFX safety components the not ways, to to relates potentially and the VEGFRX, warnings can we differentiates specifically labeling. think it the it

our of second have incredibly we first how quarter, well As it X the through pleased as into studies moving things the relates the with Phase impact, is progressed. as to that the quarter, one were

goes we program a testament asking that's that only our also to Phase RET X just differentiate, think but you're again that way also inhibitor for for study, that our global which sites that and molecules the for not beyond and a hopefully XXX, I about. have the multiple setting MET

very outlined the the RET not with the our future think, of impact which other the hard duration but program studies, So, from pandemic, MET. far been an pleased predict, for we've but enrollment to so for equally the I overall is as we've X Phase only include

would and if virtual KOLs trials, given ASCO touch to the involved for I a about you. clinical [Ph] could time you're Great, AACR connect kind of And of talk to the lot thank imagine that then of maintaining I wondering was [are how you shifts become points conferences, that in committed] you and like some with engagements? those just

of also just the than normally clinic new I more the have might past. to the unfortunately been, have and things who in and been would much the of of One at been adapting I've more focused say is recent much been been environment many online with KOLs home have as some have more they the on so, KOLs would

ongoing incredibly our changed, don't all has or, really I any been my our So at least engagement Mohammad, obviously, believe from perspective CMO, has engaged that across four of programs.

think But with that relates I we or face-to-face it's to think I approved major to unfortunate or investigators conferences. as you're the don't our medical our that it point, it obviously relates deters new to right; distracts trying don't as ongoing of any in that many connect us studies. key it are to for the drugs your that get way

sense. that so Thank Great, you makes much.

Thank you.

question next with comes from Our Wells Birchenough Jim Fargo.

is line open. Your now

sites. Yes, COVID-XX Is difficult offset you'd hi, previously? TRIDENT-X, XXX going different I patients or to seeing the on to there NTRK+ that all the of the for first that and environment. guess and the anything ROSX from in impact guys. XXX for assumed than progress you're detail, congrats just just of on screening terms Thanks through is

you to okay for Same everything question, for made Jim. family. the and your Thanks is hope I Corinne, comment

throughout evaluate back. additional trial countries looking were First, we I the making say conduct of just the decision would the to that

in detail track course, a fast Of through was of designation our of Phase granted that X given I'd lot updates context the our today.

a trial. is new additional been data, So to really sits, to Phase countries, Phase I into scale study the and that's just remind bring all X or we've may X was may evaluating folks, we time so such the appreciate global countries program, not but over seven and try more two what much our

additional as XXX more that from X. we've that think as as but outreach to outreach to to through those to for So, that actually as impact we XXX I selected, at new well a that Phase areas, it in site we're learned some KOLs CRO, prior the the our that with trying going well countries delay had included obviously selected just some the mitigate sites making, as you're seen countries as any saying potential relates point the initiations today road, to down we've we've

we will if adding can further. sites that So additional going mitigate hopefully help

to such ahead as if, it looking could extent then for give this Cohort an just certainly had still strong would TRIDENT-X. a may we Can activity? to sense that terms the of but on CNS in what wondering responses us to for. expectations update preponderance around it be Athena, And just we'd expect should patients? is just enrolled the second-half quarter, number look what where maybe Cohort patients X/X your you X/X, then And in expect response, third if be you is would confirm have you that patients what set And of of expectations you've

Sure.

having to what that in and QX prepared in today more to guidance and the local get then our in year is know, by outlined scans said I we and right relates give database. second-half. things to institution we the now relates And into our we've outline the what that inevitably overall is, we're It's right as labs the was, one of what out as tried data collected. you you into shop of local beginning centers, expect treating at many CT it as study now now the that we've in is, of and/or to sponsors monitoring to local potentially to had said what data flexibility again, allow greater have the collection, and remarks the what it So conduct patients mean we

that So are we what today But potentially do said watch collection. we're quarter. to where still going we update is to with third the we've in second-half provide have data

I And we've I too Phase assess much so, the question fully it's disease, data it time, data you've coming activated should be how cohorts patients. to disease. second-half, collected countries. have X where the those more at the the between enrolled can't in I asked to really I we What that XX in that And X cohorts. think have intracranial I be is point look will had the of kind it'll same earlier Phase to have about answer me the said difference CNS versus of at the for half multiple have countries now When study, two-country it's today about Over early X/X. how whether probably about patients made now

some to clearly more it's so add that that which global And a think would may much more trial, variability.

to two is much daily. our but an so, milligrams Phase number more to only to a reminder X want two global a XXX after countries as at look dose also a not And to patients regiment of change early of allows scale, a we assess, from be titration able weeks that

X, days. that a to You can it after daily. go seven in explore Phase dose and twice we we double didn't after period shorter the explored And

early XX utilizing small dose assessment my patients, data, which the just scale more Phase you've approximately initial I think at X want really dataset. the trial. a to looking is global consistent, said when about made, we a to XX obviously always again relatively in patient. which So is much to our I data see the We're point

Well, much. thanks that be detail. for And again all safe, so thanks

Thank you, Jim.

Thank you.

Schmidt from next comes Guggenheim. Michael Our with question

is open. line Your now

update AND said, really mature the, for what patient the Athena, based looks Good one hear seems thanks treatment the you Hey, on frontline questions, my for detailed It [indiscernible] that in the thanks PFS to cohort today. taking nicely. that. to

any Just at start [indiscernible]. X treatment curious taking you discontinuations look also from updates as it the if share a potential you study could Phase on

thank Yes, for Michael. you highlighting that,

of to of highlight, prepared we our clearly wanted the One we remarks. things course, taped

received And so, the approval. we've track fast recently designation obviously very

July central an points that we that FDA updated received maturity a yet July we was information the we've XXXX out, Having with the utilizing since cutoff, utilizing blinded, data. independent I And duration physician what so, additional two not formal there. not to the review update the of there's year. SO not also data but provided assessment looked only we've last from Previously you had analysis pointed I response would think the out. of that, said point said that at

had we XX estimated of high a being that And that so was it there months. least at XX% that likelihood,

months, of just at to has met, XX.X the again is Today, you're a over response if and trying we've duration which remembering been months. do median said historical is XX now comparison the crizotinib's median

which essentially survival, both think at for compares are it XX months. progression-free again approved to I XX.X months, at historically the agents,

we months. So were plus at a five-and-a-half looking delta,

commented patients So out and Phase we're one gave in seven we update relates pleased now are, All to as it with that that as only now subsequently multiple the previous X. extension what that is was we on with very gave the our to on today on drug, additionally years the and patients progressed. the response where two-and-a-half remain we've all treatment, January, patient of over has patients a since, in

discontinuations. gave the relates we what in update to of as it that's So terms

think color when potential and timelines? the thanks. you're predict think you at able Makes to about and activating, you then but any sense, filing complete sites the obviously how that hard enrolling additional moment we to the might And should registrational be additional re-acknowledging cohort, on first

we've site delay No, would And the said it's Today, activated, not sites a to is full of do quarter, timeline, yet timeline but the XX% QX. a seen as relates given within of study, over would to we the that it we've question. Phase guidance the we that now very for a bit we've X first yet into closer we've clearly progress with activation. that said little got have made moving we as we more fair so consistently give our

we'll believe right timeline it's do little our activation. of a be to XXX% better a provide So I and you hard we'll completion truly But all in when potentially enrollment hit that can assess trial now the we still activated position once curve. for predict a have to site sites

So question fully today. can't it's answer a I

Thank often I'm inhibitor with in based reasonably nice that see to label a in terms of should you. broad said capmatinib read very potential through Novartis a longer-term as wondering point. And path regards then approval study. the just how plan you the frontline small and to bar think very and the Novartis this MET very FDA including and with about we program well efficacy through maybe that market how as think to that has at sort of about

week before higher highest said unfortunately the for map, breast Last than add it see busy rate and of still the for that Yes. when actually was Sure. a I think as and don't cancer that the their oncology those cancer has I death, remains was unfortunately precision pancreatic and you lung it's altogether. week colon

approvals So, win was big the field. are so last positive, week a two any the me lung cancer within incredibly to for space advancements

relates XX safety Again, that might've the some I the consistently of I data making the think we think to we treatment believe differentiate benchmark it of potentially ways of population. point that patient the is prolonging to about profile. that surprised there it truly that were the as data naive still are by seen with we've duration response in related can to you're some as been months there

do the update. with always will that when asset. be we a It will we've course interested still for said within the for known of of which And second half. update will be our so be there high predominantly And program, a MET we've provide safety is again, that we edema rate peripheral us,

same their look we you're are label, correct, relatively had then conviction size that we differentiate. the both potentially in could point, think fact those your of and led as was ways when have sample And before to think the small I we the So that it a we indications. the at still I how to belief

Thanks, Athena, and great. update. appreciate Well, the

everything's very okay I Michael. for Thanks much, you. going hope

you. Thank

H.C. from Wainwright. comes Robert with question next Our Burns

now is open. line You

Hi. one, for and I my the but Most point questions one been follow-up. congrats progress Thanks and already, quarter my phenomenal questions all taking making. just answered in the is of have turning

further assets, generation think we down agents, as all you. the Thank the pathway? SHPX into taking considering on combining in consideration for these of example, resistance an inhibitors, later for off propensity So looking on mechanisms about these the and are road you inhibitor, with development development later higher and TKI target the additional

Yes, sure, very question. good

think, I question as to engagement. a medical and earlier it So was there conferences relates KOL

least our asset we're this multiple a for can I to ASCO, a important about it that at as AACR talked at investigational We've think the combination end lead inhibitor. two evaluate combined continued place be do predominantly to team our it's ways that program, strategy. repotrectinib, that our have is at EGFR RET highlight to inhibitor RET with but to now. that's we it. where while June first really we preclinical relates us quite We've but combine any there fully being to another we work be for least update on there'll aware the conferences, between the of We've show built now start will our

inability we to point, obviously then the ACR and we combine at very entire or others, looking will presentation. think targeted subsequently coming your I are whether abstracts but it's our haven't be pipeline just again, with but TKIs soon other publicly, out So while necessarily therapies, something and shown that

you. Awesome, thank

Thanks very much, Rob.

Thank you.

comes Fargo. Wells Our Birchenough next from question with Jim

Your line now is open.

for Yes. the Hi guys. Thanks follow-up. taking

becomes to wild mutation and where approaches? your where Athena front you're categories broader think frontline profile Is solvent point there the that as type preferred lung maybe the the Tagrisso hitting are the of mutations, to about in Just question, that you a good Tarceva time lung want or what's drugs, you can to for start and we some like going about get mutations. example, Thanks. that precedent prominent if to over hits wild-type an there's as be things and just frontline agent the think dominant sense cancer resistance a of cancer, something non-small-cell

Yes, sure. Jim.

update TKI-naive of I its update and years mutations. months, based a at repeatedly at is strongest show to the data reasons [indiscernible] where over have think and are median the so I think the still XX the set clearly that X as months to patients good the course, again we years close I be of then front two competitors XX perceived PFS one showing DOR and that I today's know we we've example, repotrectinib and only wild one the started Phase well positively hits in hope is the showing very that why to agent, moved has against on potency, think believe the of in as Tagrisso line as and two is best-in-class solvent-front asked type drug clinic currently now that for been activity will the of that's the I clearly

So think about we benchmarks the often out outlined example you've Tagrisso. use that when we in there, other

also we'll can it but it's that is the a very think in started molecules become now think best-in-class. for each really agent we point Al at resistance, of cancer, cell a setting be for to the and differentiate frontline fair of Kansa think but Sometimes given ALK-positive different also how treatment non-small our lung fact only not I look

the taking for follow-up. thanks Well, Great.

Jim. Thanks,

with Thank Our comes you. Partners. Capital next Instructions] [Operator question ROTH Zegbeh Jallah from

is now line Your open.

of with of TRIDENT get regional quick I of how then and about enrollment where more differences kind that of question overlap just impact sites a you're wanted to any may seeing in an for sense ask a the COVID-XX?

thank for question. the you Yes,

relates the Phase So it first, X. to versus X Phase I think as it's the

South enroller X, patients our the United was activated is within component, relates two it what Kettering, Phase them Sloan Let have say we've States at periodic now half was given the from enrollment coming, Phase XX the we over countries enrollment me X is States enrolled largest Phase United of any the or guidance so as I and say countries, but X. within the here it Korea, just Phase did today where to within and not have X

So at Phase the within broad say you of started given study. I but it have the to you haven't countries, I X has base enrollment specifically where information least given is already that a

as the today. could as relates So best that's of it way question the enrolment I that answer to

that might the happen likely for of thanks. here, many sense XQ a wanted That's duration update to scans, X? Phase another be get what just helpful, And in TRIDENT the treatment for follow-up also how will median then data

is given who institutions. we're now, that data we local that have currently patients fact multiple collected have from something That's the evaluating being still that

whether what give scans in So second-half. to will in be or post context I because you when also be whether in will will the or two dependent the QX to patients than guidance update will the be, able further it the as have would it more later of one will be, baseline any update on be

it. Got Athena. Thanks,

Of the for questions. course, thanks

you. Thank

Arlinda Lee Our question from next Canaccord. with comes

Your open. line is now

color end for the of on Hi, we I guys. be had I of additional looking was taking data questions. the my might some towards maybe for expecting the that maybe sets Thanks year.

to change Thank and be year was that middle there's since You mentioned whether last the of versus if sorry, not patients impacted were was looking patients trial you the about largely any and or started XX from biopsies XX-ish to I I by this in going archival patients arm. fresh curious again. to COVID? these those time? during last registration curious Are you anticipate any exploratory of maybe for you. late if you're, year, then And then workup issues requiring

currently Yes, for testing. enrollment documents the had We thanks. in questions, with have come local some that guided Thanks Arlinda. in patients for our can and previously again of it actually outlined

is So, patient of unless there been naive who's current no fresh a diagnosed. recently just requirement a is biopsy course, for the patient

will impact based the it is your be to to within in we patients partially will components stand question. barrier as treatment answer be were biopsy for before paradigm, the with a the data and where So able that we're analysis their relates on where through patients it to the current last coming hopefully as the trial. question again, are not The

Again, of that will answer are correct, answer why any the only in entirely potentially will whether can't your again, we had looking at asking is enrolled, that hard the but early patients overall it's was had you're and during recent timeline have, data enrolled this of dataset I the now. patients the started patients. more be July studies collection, right in we versus think have would to question that's year, than question I a likely they last but So, scans time, more contact patients

you. thank Okay,

Okay.

this I call turn questions back I'm like any for to time. not now at showing would closing the Athena you. remarks. Thank Countouriotis to over further

dialing for support Therapeutics. everybody your appreciate again interest in I time, Point you thank Turning in. the Well, and really and obviously

of the for under all you. so, during well at you now and you I employees know operator, families that is Given close And have Thank directive, many unprecedented stay-at-home times. home, may you everything the that. company and your call. thank the know our are you of I doing, been hope stay these I you

gentlemen, call. for Ladies participating. you and today's concludes this Thank conference

disconnect. now may You